Select Page

KADCYLA ™ (ado-trastuzumab emtansine) for injection, for intravenous use.

KADCYLA ™ (ado-trastuzumab emtansine) for injection, for intravenous use.

KADCYLA is a prescription medicine. KADCYLA is used to treat HER2-positive breast cancer.

KADCYLA is a HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane,separately or in combination. Patients should have either:
• Received prior therapy for metastatic disease, or
• Developed disease recurrence during or within six months of completing adjuvant therapy.
Lyophilized powder in single-use vials containing 100 mg per vial or 160 mg per vial.
Manufactured By: Genentech
Prescribing Information URL: Click Here

Procedure to buy KADCYLA ™ (ado-trastuzumab emtansine) for injection?
To buy KADCYLA ™ (ado-trastuzumab emtansine) for injectio, patients can simply fill the order form or can send mail at or can also send Whatsapp message at +91 96677 50889. You will get reply within few hours with pricing and procedure details. Note:- the order will be confirmed only after the receipt of valid prescription of doctor.


Trastuzumab emtansine also known as ado-trastuzumab emtansine and sold under the trade name Kadcyla, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to the cytotoxic agent DM1.

In the United States, ado-trastuzumab emtansine was approved specifically for treatment of HER2-positive metastatic breast cancer (mBC) in patients who have been treated previously with trastuzumab and a taxane (paclitaxel or docetaxel), and who have already been treated for mBC or developed tumor recurrence within six months of adjuvant therapy.

Approval was based on the EMILIA study,[10] a phase III clinical trial that compared trastuzumab emtansine versus capecitabine (Xeloda) plus lapatinib (Tykerb) in 991 people with unresectable, locally advanced or metastatic HER2-positive breast cancer who had previously been treated with trastuzumab and taxane chemotherapy.[10] This trial showed improved progression-free survival in patients treated with trastuzumab emtansine (median 9.6 vs. 6.4 months), along with improved overall survival (median 30.9 vs. 25.1 months) and safety.


  1. Doctor’s Prescription – We would require prescription from registered medical practitioner stating product name, dosage, duration of treatment and diagnosis.
  2. Patient’s Medical history – We would require all test reports and medical reports of the patient for last 3 months.
  3. Patient’s Identity card – We will require scan copy of patient’s identity card and proof of residence to initiate documentation process. you can use copy of passport, driving license, employee ID card or any photo id document as your identity card.

For Overseas Patient

Can I get anti-cancer medicines even if I am not based in India?

Almost all countries across the world have provisions for granting access to drugs prior to marketing approval for personal use for patients who have exhausted all other treatment options available in their country. The Bionique Healthcare can help patients in accessing/importing Ant-cancer medicines, unapproved in their home country against a legitimate prescription and in conformity with all local laws and regulations of their home country.

Send your query to find the best price of –

KADCYLA ™ (ado-trastuzumab emtansine) for injection in South East Asia – China (Beijing, Chongqing, Shanghai, Tianjin and Shenzhen), Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong.
KADCYLA ™ (ado-trastuzumab emtansine) for injection in United Arab Emirates – Iraq, Iran, Saudi Arabia, Jordan.
KADCYLA ™ (ado-trastuzumab emtansine) for injection in North America – Mexico.
KADCYLA ™ (ado-trastuzumab emtansine) for injection in South America – Argentina, Brazil, Chile, Colombia, Peru, Venezuela.
KADCYLA ™ (ado-trastuzumab emtansine) for injection in Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia.
KADCYLA ™ (ado-trastuzumab emtansine) for injection in Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia.
KADCYLA ™ (ado-trastuzumab emtansine) for injection in African Countries – Algeria, Mauritius, Uganda, Zimbabwe.
KADCYLA ™ (ado-trastuzumab emtansine) for injection in Australia and New Zealand.

For Indian Patient

<strong>Ani-Cancer KADCYLA ™ (ado-trastuzumab emtansine) for injection are prescription drug. </strong>

<strong>We facilitate by-</strong>
<li>Helping in documentation to import the medicine for personal use.</li>
<li>Finding Genuine and reliable source in USA, Europe and Japan.</li>
<li>Ensuring 100% transparency.</li>
<strong> KADCYLA ™ (ado-trastuzumab emtansine) for injection can be shipped</strong> <strong>to Ahmedabad, Bangalore, Chennai, Cochin, Hyderabad, Delhi, Haryana, Jaipur, Jammu and Kashmir, Himachal Pradesh, Kolkata, Lucknow, Mumbai, Pune, Punjab and other cities in India.</strong> <em><strong>Bionique Healthcare does not manufacture, supply, re-sell or retail any drugs or medicines.</strong> </em>


There are no reviews yet.

Be the first to review “KADCYLA ™ (ado-trastuzumab emtansine) for injection, for intravenous use.”

Your email address will not be published.

Anti-Cancer Medicine Supplier.

Bionique Healthcare is a consulting pharmaceutical company which assist Patients in accessing medicines in India. Bionique Healthcare facilitates such access only against valid prescriptions in conformity with all local laws and regulations.

Patients/ Clinicians / Researchers can contact Bionique at +91 9667750889 or write to at –

Product Disclaimer

Bionique Healthcare does not manufacture, supply, re-sell or retail any drugs or medicines. All trademarks and other intellectual property in relation to drugs and medicines supplied to you by suppliers are owned by their respective manufacturer or licensee. 

Bionique Healthcare does not lay any claim on them.